# A Study to Determine the Bioavailability of Lanadelumab (SHP643) Administered Subcutaneously With the Prefilled Syringe and the Autoinjector in Healthy Adult Volunteer Participants.

> **NCT03918239** · PHASE1 · COMPLETED · sponsor: **Shire** · enrollment: 190 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** SHP643

## Key facts

- **NCT ID:** NCT03918239
- **Lead sponsor:** Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-14
- **Primary completion:** 2019-11-13
- **Final completion:** 2019-11-13
- **Target enrollment:** 190 (ACTUAL)
- **Last updated:** 2020-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03918239

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03918239, "A Study to Determine the Bioavailability of Lanadelumab (SHP643) Administered Subcutaneously With the Prefilled Syringe and the Autoinjector in Healthy Adult Volunteer Participants.". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03918239. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*